But patients would rather treat their sleep apnea with tirzepatide (Zepbound), a GLP-1 weight-loss drug, researchers found. "The results highlight a need for real-world comparative effectiveness ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ethical issues and prices that are still too high for many patients.

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Key Takeaways Patients and doctors are disagreeing about sleep apnea treatmentDoctors favor the use of CPAP machinesBut patients with obesity would rather use Zepbound to ease their apnea MONDAY ...

But Zepbound is only for people with obesity and sleep apnea, the AASM noted. Also, Zepbound can reduce the severity of sleep apnea through weight loss but might not cure the problem.

People with insomnia and concomitant obstructive sleep apnea (OSA) represented a fairly common, medically complex group for ...

Staff at a sleep clinic in France place monitor leads on a patient in preparation for a polysomnography. This exam is considered the gold standard for diagnosing sleep apnea, a disorder that ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.